Stock Analiz

aTYR PHARMA INC ATYR

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2015 · data as of November 13, 2026

$6.11Market cap $16M
Open the interactive analysis →

aTYR PHARMA INC (ATYR) is a healthcare company listed in the US with a market value of about $16M. In fiscal year 2025 it had revenue of $190000 and net income of -$74M, a net margin of -39009.5%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).

Key numbers: a P/E of 0.3, 5-year revenue growth of -55% a year, a 5-year average ROIC of -64%.

About aTYR PHARMA INC

aTYR PHARMA INC is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2015. Revenue went from $422000 in 2019 to $190000 in 2025, a decline of about 12.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 227% over three years (dilution for shareholders). It spends 31694% of revenue on research and development.

Score: 0.8 / 5

Value2/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)0.3
Forward P/E—
P/FCF—
P/S—
P/B0.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-281.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-19.1%
Revenue growth (5 yrs, per year)-55.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-20241.1%
ROIC (5-yr avg.)-64.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$190000$235000$353000$10M$0$10M$422000———
Net income-$74M-$64M-$50M-$45M-$34M-$16M-$16M-$35M-$48M-$58M
Free cash flow-$62M-$69M-$37M-$44M-$33M-$16M-$20M-$32M-$44M-$53M
EPS (diluted)$-0.80$-0.86$-0.94$-1.60$-1.77$-1.77$-7.03$-16.11$-26.13$-34.13
Net margin-39009.5%-27243.8%-14274.5%-436.5%—-155.2%-3844.6%———
ROIC-98.7%-83.0%-52.7%-54.9%-30.7%-46.9%-69.8%-61.7%-44.4%-80.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $45.17, 640% above the current price; targets range from $5.00 to $160.00; the consensus rating is “Hold”; expected EPS is $-23.97 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is aTYR PHARMA INC’s P/E ratio?

About 0.3, based on the last twelve months of diluted earnings per share.

Does aTYR PHARMA INC pay a dividend?

Not currently.

Is aTYR PHARMA INC a good stock to buy?

We do not give buy or sell advice. aTYR PHARMA INC scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.